Voriconazole inclusion complexes

A method of stabilizing a lyophilized solid voriconazole formulation, comprising

• dissolving a substituted β-cyclodextrin characterized by a molar substitution of the β-cyclodextrin by hydroxypropyl groups of more than 0.8 and voriconazole in an aqueous vehicle including no organic solvents to form a dissolved composition, wherein the dissolved composition has pH of 4-7, and
• lyophilizing the dissolved composition comprising the voriconazole and the substituted β-cyclodextrin characterized by a molar substitution of the β-cyclodextrin by hydroxypropyl groups of more than 0.8 to provide a stabilized lyophilized solid voriconazole formulation,
• provided that the stabilized lyophilized solid pharmaceutical formulation does not comprise lactose.